Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Colorcon
US Army
Queensland Health
Deloitte
Cipla
Moodys
Daiichi Sankyo
Fish and Richardson

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021991

« Back to Dashboard

NDA 021991 describes ZOLINZA, which is a drug marketed by Merck and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug. Additional details are available on the ZOLINZA profile page.

The generic ingredient in ZOLINZA is vorinostat. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vorinostat profile page.
Summary for 021991
Tradename:ZOLINZA
Applicant:Merck
Ingredient:vorinostat
Patents:9
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 021991
Generic Entry Date for 021991*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 021991
Suppliers and Packaging for NDA: 021991
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZOLINZA vorinostat CAPSULE;ORAL 021991 NDA Merck Sharp & Dohme Corp. 0006-0568 0006-0568-40 120 CAPSULE in 1 BOTTLE (0006-0568-40)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength100MG
Approval Date:Oct 6, 2006TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Feb 9, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
Patent:➤ Try a Free TrialPatent Expiration:Mar 11, 2027Product Flag?Substance Flag?YDelist Request?
Patent:➤ Try a Free TrialPatent Expiration:Mar 4, 2023Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021991

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Accenture
Baxter
Healthtrust
Covington
Chubb
UBS
QuintilesIMS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.